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People with chronic hepatitis B (CHB) are a major 
source of incident hepatitis B virus (HBV) infection. 
The Department of Health in Victoria, Australia, recom-
mends household contacts of CHB cases to be screened 
and funds hepatitis B vaccination for those susceptible 
to infection. In July 2009, two cross-sectional surveys 
were conducted to assess the uptake of screening and 
vaccination: a postal survey of the treating doctors of 
a random sample of 65 CHB patients and a telephone 
survey of these patients. Twenty-six cases reported all 
adult household contacts had been screened, however 
only eight of these 26 patients reported that all sus-
ceptible adult contacts had been fully vaccinated. In 
contrast, child contacts of only three cases had been 
screened but 15 reported all child contacts to be fully 
vaccinated. Half of the surveyed doctors were unaware 
of state-funded hepatitis B vaccine for contacts and 
only 10 had conducted any contact tracing. This study 
highlights the need for health departments to play 
a greater role in the management of CHB patients in 
order to support doctors’ delivery of preventive serv-
ices to people at high risk of HBV infection. These find-
ings are relevant for all countries receiving immigrants 
from areas where hepatitis B is endemic.
Introduction 
Worldwide, about 2x109 people have been infected 
with the hepatitis B virus (HBV), and more than 350 mil-
lion live with chronic hepatitis B (CHB) virus infection 
[1]. Estimates of mortality attributable to CHB range 
from 600,000 to over 1 million deaths annually [1-3]. 
Australia is a low-prevalence country, with a hepati-
tis B surface antigen (HBsAg) prevalence of less than 
2% [4-6]. Over the last 20 years, however, the preva-
lence of CHB has increased, predominantly related to 
the increase in migration from highly endemic regions 
[7,8]. Currently there are an estimated 165,000 people 
with CHB infection in Australia, more than half of whom 
were born in other countries of the Asia-Pacific region 
[7-9]. About 55,000 of those infected are unaware of 
their diagnosis [10,11]. Predominant risk factors for 
CHB in Australia are birth in a high prevalence country 
or being an Aboriginal or Torres Strait Islander [7].
In Australia, hepatitis B infections are reported as 
acute or unspecified (non-acute). Unspecified hepati-
tis B (herein referred to as CHB) requires detection of 
HBsAg, or HBV by nucleic acid testing, in a patient with 
no prior evidence of HBV who does not meet criteria 
for acute infection [12.] In Victoria, from 1998 to 2008, 
there were a total of 19,024 cases of confirmed CHB 
reported through the notifiable disease surveillance 
system, with between 1,497 and 1,938 cases annually 
[13]. Notification rates for CHB in the Melbourne met-
ropolitan region were significantly higher than in non-
metropolitan regions of Victoria, reflecting findings of 
a recent serosurvey [14]. 
CHB is associated with significant morbidity and mor-
tality. Approximately 25% of people with CHB develop 
advanced liver disease including cirrhosis and/or 
hepatocellular carcinoma (HCC) [3,15]. This excess mor-
tality was demonstrated in a recent data linkage study 
in New South Wales, Australia that found that people 
living with CHB had standardised all-cause mortality 
1.4 times higher than those without CHB [10]. In New 
South Wales, HCC incidence is rising faster than any 
other internal cancer [16,17].
In Australia, universal hepatitis B vaccination for 
adolescents commenced in 1998 and for infants in 
2000, with the first of four doses given at birth [9]. 
In Victoria, in addition to the national immunisation 
programme, hepatitis B vaccination is funded for 
healthcare workers, people who inject drugs, and 
household or sexual contacts of patients with CHB 
and people living with human immunodeficiency virus 
or acquired immunodeficiency syndrome (HIV/AIDS) 
[18]. Serologic testing before vaccination is recom-
mended for families of CHB patients, as well as for 
members of families who have migrated from high-
prevalence countries [5].
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Chronically infected individuals are a source of inci-
dent infections (in low and high prevalence countries 
alike) [19-22]. Furthermore, persons with undiagnosed 
CHB can remain asymptomatic for years and unaware 
of their risk for transmitting the virus to others or 
having liver disease in later life [21,23]. Therefore an 
adequate public health response to incident HBV infec-
tions must reduce opportunities for transmission from 
those chronically infected to those who are susceptible 
[21,22]. 
Currently it is unknown whether or not tracing the 
household contacts of CHB patients takes place in 
accordance with Victorian recommendations, and the 
uptake of the funded hepatitis B vaccine for contacts 
of CHB patients has not been evaluated. Consequently, 
the objectives of this study were firstly, to ascertain 
the uptake of screening and vaccination in household 
contacts of patients with CHB, and secondly, to explore 
barriers to vaccination amongst household contacts of 
CHB cases.
Methods
Study population 
Patients were randomly selected from the Notifiable 
Infectious Diseases Surveillance database maintained 
by the Victorian Department of Health. Patients were 
eligible for the study if they were notified to the depart-
ment with CHB between 1 July 2008 and 31 December 
2008 (n=989). Our target sample size was 65 patients. 
Patients were excluded if no notifier details were 
recorded, or if no contact details for the cases were 
available after checking with the notifying doctor and/
or laboratory. 
Study design
In Victoria, if a patient is randomly selected from the 
surveillance database as part of a study, it is custom-
ary that treating doctors are contacted first to ensure 
the patient is aware of their diagnosis prior to invit-
ing their participation. We conducted two cross-sec-
tional surveys to gather information from doctors and 
patients about patients and their household contacts.
The first survey was a postal survey sent to the doctors 
of 65 patients randomly selected from the 989 CHB 
patients. The second was a telephone survey of those 
patients whose treating doctor had given consent for 
the investigators to contact their patient. On calling 
patients, a confidentiality statement was read to each 
patient, verbal consent obtained and an appointment 
was made to interview them.
The doctor survey assessed knowledge of the Victorian 
recommendations regarding the hepatitis B vaccine and 
attitudes about a doctor’s role in contact tracing. It also 
assessed whether the doctors had attempted to trace 
household contacts of their patient in the sample, and 
if so, whether they documented the screening and vac-
cination status of their patients’ household contacts. 
The patient survey assessed the uptake of screening 
and vaccination of household contacts following the 
index patient’s diagnosis. Interviews were conducted 
with an interpreter when necessary. The principal out-
come was the proportion of patients whose suscep-
tible household contacts had been fully vaccinated 
against hepatitis B. Patients were asked for each con-
tact’s age, screening history, and if susceptible to HBV, 
the number of doses of hepatitis B vaccine received. 
Vaccination of contacts and serologic confirmation of 
immunity were reported by the patients and not oth-
erwise verified, and reasons for non-vaccination were 
sought when applicable. 
A secondary aim of the patient survey was to assess 
knowledge regarding hepatitis B transmission by ask-
ing respondents to provide an example of how to pre-
vent the spread of hepatitis B infection. Patients were 
considered to have an understanding of preventing 
spread if they stated any one of the following methods: 
no sharing of certain household items such as razors, 
keeping wounds covered, practising safe sex, no dona-
tion of blood or organs, or vaccination of contacts. 
Data analysis
Data were entered into Microsoft Access and analyses 
conducted using STATA v9. Household contacts’ vacci-
nation status was analysed according to each patient 
because household contact observations are not inde-
pendent. If all adult and/or child contacts of a patient 
had been tested or vaccinated, this was considered a 
positive outcome. If a patient was uncertain about the 
status of any contact, all contacts of that patient were 
excluded from the analysis. 
Ethics
Human research ethics approval was granted by 
The Australian National University (Study number 
2009/552).
Results
The surveys were conducted in June and July 2009. 
Twenty-four doctors returned the surveys and two 
doctors were interviewed by telephone for a doctor 
response rate of 26 of 65. We telephoned the 39 doc-
tors who had not responded to the postal survey and 
obtained consent from 21 of them to call their patient. 
Therefore a total of 47 patients were eligible. Of these, 
four patients were unable to be contacted and doctors 
of five patients requested their patient not be con-
tacted by the investigators. The remaining 38 patients 
all agreed to participate in the study.
Doctor survey 
The majority of doctors who participated in the study 
were metropolitan general practitioners (GPs) (23/26). 
Others included two hospital-based doctors and one rural 
GP. Of 39 non-responders, 37 were metropolitan GPs and 
the remaining two represented private blood screening 
services. As our sampling frame was CHB patients, doc-
tors that did and did not participate in our study reflect 
3www.eurosurveillance.org
that CHB notifications are concentrated in metropolitan 
regions and largely managed in primary care settings.
Thirteen of 26 doctors were aware that hepatitis B vac-
cine for household contacts of CHB cases was funded 
by the Victorian Department of Health. All doctors 
agreed that general practitioners have a role in contact 
tracing for hepatitis B, however only 10 indicated that 
they had attempted contact tracing for their patient. 
Nine doctors suggested reasons for non-uptake of vac-
cination in household contacts: language and cultural 
barriers (n=3), the perceived impact of having hepatitis 
B on Australian residency applications (n=2), and dif-
ficulty systematically following up contacts (n=4).
Patient survey 
The study population consisted of 47 patients of which 
24 were male and 23 were female. The median age at 
notification for all patients was 34 years (interquartile 
range (IQR) 27–44 years).(Table 1). Forty-four patients 
lived in metropolitan Melbourne. Seven patients were 
interviewed with an interpreter. 
Forty-four patients were born overseas. Approximately 
half of them were born in Vietnam (n=12) and China 
(n=11) (Table 2). Information on the year of their arrival 
in Australia was available for 39 of these patients and 
ranged from 1958 to 2008. More than two thirds of the 
39 patients (n=26) had arrived since 2000. For patients 
born overseas, the median time between arrival in 
Australia and notification with CHB was five years (IQR 
1–17 years). 
Of 38 patients interviewed, 18 had been aware of 
their hepatitis B infection up to several years prior to 
notification in 2008. Eleven of these 18 patients had 
been tested in their country of birth prior to arrival 
in Australia. For patients diagnosed in their coun-
try of birth, the median time between first diagnosis 
and notification in Australia was 8.5 years (IQR 2.5–11 
years).
Of the 32 patients who answered the question 
about transmission of hepatitis B, the most common 
responses were avoiding unprotected sex (n=8) or 
avoiding blood donation (n=7). Thirteen patients were 
unable to give an example of how to prevent the spread 
of the virus. Two patients said that not sharing cups 
and spoons prevented the spread and one patient 
believed the virus was transmitted by food. Only one 
patient suggested vaccination of family members pre-
vented the transmission of the virus.
Household contact vaccination results
Household contact information was available for 41 
patients. Patients commonly had one adult household 
contact (n=19) and no contacts under the age of 18 
Table 1
Patient demographics, hepatitis B patients, Victoria, 
1 July–31 December 2008 (n=47)
a For whom this information as known.
    Number Percentage
Sex
Male 24 51%
 
Female 23 49%
Total 47 100%
Age (years)
10–17 1 2%
18–29 16 34%
30–49 22 47%
 
50–69 6 13%
70–89 2 4%
Total 47 100%
Region of residence
 
Metropolitan 44 94%
Rural 3 6%
Total 47 100%
Country of birth
 
Australia 3 6%
Overseas 44 94%
Total 47 100%
Years of arrivala
1950–1959 2 5%
1960–1969 1 3%
1980–1989 4 10%
 
1990–1999 6 15%
2000–2008 26 67%
Total 39 100%
Table 2
Countries of birth, hepatitis B patients, Victoria,  
1 July–31 December 2008 (n=44)
Countries of birth Number Percentage
Vietnam 12 27%
China 11 25%
New Zealand 3 7%
Burma 3 7%
Sudan 2 5%
Cambodia 2 5%
Thailand 2 5%
Afghanistan 1 2%
India 1 2%
Greece 1 2%
Romania 1 2%
Italy 1 2%
Liberia 1 2%
Bangladesh 1 2%
Kuwait 1 2%
Netherlands 1 2%
Total 44 100%
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(n=17). For 37 of these 41 patients, household contacts 
included family members only. 
Twenty-six patients reported that all adult household 
contacts had been tested for hepatitis B. Testing histo-
ries of all child contacts were available for 21 patients 
and of these, only three cases reported all eligible 
child contacts had been tested (Table 3). Children were 
considered eligible for testing if they were older than 
18 months of age.
Information about vaccination of all eligible adult con-
tacts was available for 26 patients, and of all eligible 
child contacts, for 20 patients. Eligible adult contacts 
of 8 (31%, 95% confidence interval (CI): 12–50%) of 26 
patients were reported to be fully vaccinated against 
hepatitis B. In contrast, the majority of patients with 
eligible child contacts (75%, 95% CI: 54–96%) reported 
that all had been fully vaccinated (Table 3). Child vac-
cination had occurred as part of the national immu-
nisation programme in 11 patients, whereas the child 
contacts of four patients had been vaccinated as part 
of contact tracing despite being eligible for participa-
tion in the national immunisation programme (Table 3).
Barriers to screening and vaccination of contacts
Patients were asked for the reasons why any of their 
contacts were not vaccinated. Of 38 eligible adult 
contacts, responses were provided for 34 contacts of 
22 patients. Most commonly, the patient reporting on 
the contact did not know the reason for non-vaccina-
tion (n=19) and least commonly the contact had refused 
vaccine (n=2). Four contacts were reported to be plan-
ning to start vaccination and ‘other’ reasons were 
stated for nine contacts. Only five patients expanded 
on ‘other’ reasons, which were fear of testing for hepa-
titis B, being unaware of the need for vaccination, liv-
ing overseas, awaiting blood test results, and difficulty 
attending the GP.
Discussion
Our study showed that, despite recommendations for 
contact tracing and funded hepatitis B vaccine, the adult 
household contacts of less than a third of CHB patients 
had been vaccinated against hepatitis B. In contrast, 
the child household contacts of 75% of patients were 
reported to be fully vaccinated, mostly attributable to 
universal vaccination. We found it concerning that only 
half of the surveyed doctors were aware that hepati-
tis B vaccine was funded for household contacts. This 
is likely to be a key provider barrier to vaccination of 
household contacts [24]. All surveyed doctors felt that 
GPs have a role to play in contact tracing, however only 
37% had conducted any contact tracing for their noti-
fied patient. We inferred that this was due to lack of 
knowledge of funded vaccination policy and to the dif-
ficulty of organising contact management, especially 
if contacts were not patients of the doctor’s practice. 
Currently the Victorian Health Department relies on 
doctors to manage the contact tracing, however our 
small study suggests this assumption may need revis-
iting. Doctors’ efforts to provide preventive services to 
populations at high risk for infection may benefit from 
public health collaboration [20].
Although 26 of 38 patients reported their contacts had 
been screened for hepatitis B, only a small number had 
been vaccinated. This suggests that being tested (and 
reported to be susceptible) is not necessarily sufficient 
to ensure participation in vaccination. It is worrying 
that only eight of 26 patients reported that all their 
adult contacts had been fully vaccinated, but it is con-
sistent with published findings from other countries: In 
the United States, a study in San Diego found less than 
20% of eligible contacts (including children) had been 
vaccinated, and in the United Kingdom (UK), a similar 
study found only 27% of contacts had been vaccinated 
[20,25]. A 10-year seroprevalence review of hepatitis B 
in Italy also found 28% of new HBV cases were house-
hold contacts of CHB patients and had been unaware 
that free vaccine was available [26]. 
The limitations of this study included the small sample 
size of doctors and of patients that provided vaccina-
tion status of all of their contacts. In addition, obtain-
ing a serological assessment of contacts’ vaccination 
status would have strengthened the study, but this was 
not feasible. Previous studies have shown poor patient 
recall of their own vaccination status [27], therefore 
Table 3
Testing and vaccination data of household contacts of 
hepatitis B patients, Victoria, 1 July–31 December 2008 
(n=41 patients)  
Number Percentage 95% CI
Patients for whom all adult contacts were screened
Yes 26 68% 53-84%
No 12 32% 16-47%
Total 38 100%  
Patients for whom all eligible child contacts were screened
Yes 3 14% 0-31%
No 18 86% 69-100%
Total 21 100%  
Patients whose adult contacts were all fully vaccinated
Yes 8 31% 12-50%
No 18 69% 50-88%
Total 26 100%  
Patients whose child contacts were all fully vaccinated
Yes 15 75% 54-96%
No 5 25% 4-46%
Total 20 100%  
Reason why children were vaccinated
National immunisation 
programme 16 80% 61-99%
Contact tracing 4 20% 1-39%
Total 20 100%  
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it is be reasonable to assume that recall of contacts’ 
vaccination would also be poor. However, this may not 
have affected parents’ recall of the vaccination history 
of their children as much as their recall of the status 
of other adult contacts. Uncertainty was partially man-
aged at the analysis stage by excluding patients who 
were unsure of the vaccination status of one or more of 
their contacts. 
Despite the study limitations, we feel that the findings 
build the argument for increasing public health collab-
oration in the management of chronic hepatitis B. It is 
a challenge for public health practitioners to increase 
participation in preventive programmes among high 
risk groups, who are often the most difficult to reach 
[28,29]. However for CHB in Australia, this relies on 
individual private doctors to implement public health 
policies. There is evidence that high participation 
(>90%) of contacts in screening and vaccination can be 
achieved when integrated into current clinical models 
[30,31]. In Victoria, one intervention that could be intro-
duced is direct communication of health information 
by mail or electronic mail between the health depart-
ment and notified CHB patients. This aligns with the 
principles of the Ottawa Charter that communicating 
important health information is necessary to empower 
patients to manage their health [32], and could have 
the secondary benefit of improving the success of con-
tact management [33]. Indeed, in a 2006 cohort study 
in the UK, receipt of written information about hepa-
titis B was positively associated with infants born to 
HBsAg-positive mothers completing hepatitis B vacci-
nation [34].
This issue is not limited to Australia. In Europe there is 
geographical variation in the prevalence of HBV infec-
tion given the mixture of countries with medium and 
low HBsAg prevalence [22,35]. Furthermore, an increas-
ing number of immigrants to Europe, often from highly 
endemic countries, is changing the hepatitis B epide-
miology in low endemic countries [35]. In 2009, a sur-
vey of 25 European Union Member States plus Norway 
and Iceland revealed that 20 had universal hepatitis B 
vaccination programmes in addition to targeting spe-
cific risk groups, while seven countries maintained 
hepatitis B vaccine for risk groups only [36]. Close 
family contacts of CHB cases were included in the risk 
groups in 18 of the 20 countries with routine immuni-
sation and in all seven countries with selective immu-
nisation programmes. Only 10 of 17 countries reported 
that vaccine was free to all people at increased risk by 
lifestyle, which included household contacts [36]. The 
experience in Australia suggests that the implementa-
tion of these targeted vaccination policies may need 
evaluation. 
In conclusion, the findings from our study suggest that 
the vaccination of adult household contacts of CHB 
patients is inadequate. Although child contacts born 
in Australia were more likely to be fully immunised, 
this was largely due to the national immunisation 
programme. Our findings suggest that barriers to con-
tact tracing include a lack of patient knowledge regard-
ing CHB, limited awareness on the part of doctors of 
the funded vaccine, and limited capacity of individual 
doctors to organise systematic follow up of patients’ 
contacts. Although more information is needed about 
the uptake of, and barriers to, screening and vaccina-
tion of contacts of patients with CHB in Victoria, we 
believe that information from this study should inform 
policy and programme considerations. There is evi-
dence that active contact tracing for CHB patients can 
result in high participation rates in at-risk populations 
and that contact tracing is not always integrated into 
the core business of general practice. Improved com-
munication from the health department directly to CHB 
patients, better targeted screening, and integrated 
contact tracing programmes will be vital to tackling the 
growing burden of complications from CHB in Australia. 
These findings are relevant to other countries with high 
net migration from areas with medium to high HBsAg 
prevalence.
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